Authors

• Clare Bailey (ORCID: https://orcid.org/0000-0003-2141-4512)
• Tobias Machewitz
• Helmut Allmeier (ORCID: https://orcid.org/0000-0002-5165-4851)
• Peter Morgan-Warren
• James Talks (ORCID: https://orcid.org/0000-0001-6126-6476)
• Praveen J. Patel (ORCID: https://orcid.org/0000-0001-8682-4067)
• Richard Peter Gale (ORCID: https://orcid.org/0000-0002-8847-044X)
• Deepali Varma
• Hellen McGoey (ORCID: https://orcid.org/0000-0002-9579-9390)
• Manju Chandran (ORCID: https://orcid.org/0000-0001-9119-8443)
• Nirodhini Narendran
• Zinab Keshk

Institutions

• Allen Institute for Brain Science (US)
• Moorfields Eye Hospital NHS Foundation Trust (GB)
• Aston University (GB)
• University Hospitals Bristol NHS Foundation Trust (GB)
• Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
• Frimley Health NHS Foundation Trust (GB)
• National Institute for Health and Care Research (GB)
• Sunderland Eye Infirmary (GB)
• York Teaching Hospital NHS Foundation Trust (GB)
• Bayer (Switzerland) (CH)
• South Tyneside and Sunderland NHS Foundation Trust (GB)
• The Royal Wolverhampton NHS Trust (GB)
• Bayer (United Kingdom) (GB)
• University College London (GB)
• University of York (GB)
• Bayer (Germany) (DE)
• Hull York Medical School (GB)

Publication Details

Journal

Eye

Published

2024-12-24

DOI

https://doi.org/10.1038/s41433-024-03550-y

Citations

1

Primary Topic

Retinal Diseases and Treatments

Type

article

Field-Weighted Citation Impact

0.54

Funders

• Bayer
• Bayer, United Kingdom